- Home
- FGB vs ICCC Comparison
FGB vs ICCC Comparison
Compare FGB & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGB
- ICCC
- Stock Information
- Founded
- FGB 2007
- ICCC 1982
- Country
- FGB United States
- ICCC United States
- Employees
- FGB N/A
- ICCC N/A
- Industry
- FGB Finance/Investors Services
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- FGB Finance
- ICCC Health Care
- Exchange
- FGB Nasdaq
- ICCC Nasdaq
- Market Cap
- FGB 57.5M
- ICCC 61.3M
- IPO Year
- FGB N/A
- ICCC 1987
- Fundamental
- Price
- FGB $4.11
- ICCC $5.90
- Analyst Decision
- FGB
- ICCC
- Analyst Count
- FGB 0
- ICCC 0
- Target Price
- FGB N/A
- ICCC N/A
- AVG Volume (30 Days)
- FGB 53.0K
- ICCC 27.4K
- Earning Date
- FGB 01-01-0001
- ICCC 08-12-2025
- Dividend Yield
- FGB 8.92%
- ICCC N/A
- EPS Growth
- FGB N/A
- ICCC N/A
- EPS
- FGB N/A
- ICCC N/A
- Revenue
- FGB N/A
- ICCC $27,302,766.00
- Revenue This Year
- FGB N/A
- ICCC N/A
- Revenue Next Year
- FGB N/A
- ICCC N/A
- P/E Ratio
- FGB N/A
- ICCC N/A
- Revenue Growth
- FGB N/A
- ICCC 28.29
- 52 Week Low
- FGB $2.85
- ICCC $3.34
- 52 Week High
- FGB $3.74
- ICCC $7.60
- Technical
- Relative Strength Index (RSI)
- FGB 55.64
- ICCC 50.09
- Support Level
- FGB $3.98
- ICCC $6.14
- Resistance Level
- FGB $4.17
- ICCC $6.58
- Average True Range (ATR)
- FGB 0.06
- ICCC 0.25
- MACD
- FGB -0.00
- ICCC -0.07
- Stochastic Oscillator
- FGB 50.00
- ICCC 1.15
About FGB First Trust Specialty Finance and Financial Opportunities Fund
First Trust Specialty Fnc & Fncl Oppor is a United States-based closed-end management investment company. The Fund's primary investment objective is to seek a high level of current income. It seeks a positive total return as a secondary objective. The Fund seeks to achieve its investment objectives by investing at least 80% of its Managed Assets in a portfolio of securities of specialty finance and other financial companies.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.